Adam Scott Levy

This profile gathers the share dealings of Adam Scott Levy in Mineralys Therapeutics, Inc., where the filings describe the role as finance chief. The record holds 12 filings, for trades running from 14 February 2023 to 19 February 2026.

In open-market terms, that means 1 purchase worth €93k on one side and 9 sales worth €2.5M on the other. Taken together, the sales exceed the purchases by €2.4M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 1 share grant and 1 option exercise. In 2026 alone, the filings show no purchases and 1 sale.

Most recently, on 20 February 2026, the filings show a share grant in Mineralys Therapeutics, Inc. The last insider purchase was made public on 16 February 2023, 1,340 days ago. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.